Loading...
XNYSWST
Market cap24bUSD
Dec 26, Last price  
333.43USD
1D
0.20%
1Q
7.21%
Jan 2017
293.06%
Name

West Pharmaceutical Services Inc

Chart & Performance

D1W1MN
XNYS:WST chart
P/E
40.69
P/S
8.19
EPS
8.19
Div Yield, %
0.24%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
11.43%
Revenues
2.95b
+2.18%
541,600,000699,700,000913,300,0001,020,100,0001,051,100,0001,055,700,0001,104,700,0001,192,300,0001,266,400,0001,368,400,0001,421,400,0001,399,800,0001,509,100,0001,599,100,0001,717,400,0001,839,900,0002,146,900,0002,831,600,0002,886,900,0002,949,800,000
Net income
593m
+1.28%
19,400,00045,600,00067,100,00070,700,00086,000,00072,600,00065,300,00075,500,00080,700,000112,300,000127,100,00095,600,000143,600,000150,700,000206,900,000241,700,000346,200,000661,800,000585,900,000593,400,000
CFO
777m
+7.25%
68,900,00085,600,000143,800,000129,200,000135,000,000137,700,000138,300,000130,700,000187,400,000220,500,000182,900,000212,400,000219,400,000263,300,000288,600,000367,200,000472,500,000584,000,000724,000,000776,500,000
Dividend
Jul 31, 20240.2 USD/sh
Earnings
Feb 13, 2025

Profile

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
URL
https://www.westpharma.com/
IPO date
Jul 27, 1923
Employees
10,700
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,949,800
2.18%
2,886,900
1.95%
2,831,600
31.89%
Cost of revenue
1,889,000
1,809,200
1,708,600
Unusual Expense (Income)
NOPBT
1,060,800
1,077,700
1,123,000
NOPBT Margin
35.96%
37.33%
39.66%
Operating Taxes
122,300
114,700
107,200
Tax Rate
11.53%
10.64%
9.55%
NOPAT
938,500
963,000
1,015,800
Net income
593,400
1.28%
585,900
-11.47%
661,800
91.16%
Dividends
(57,000)
(54,100)
(51,100)
Dividend yield
0.21%
0.30%
0.14%
Proceeds from repurchase of equity
(451,200)
(194,000)
(114,800)
BB yield
1.70%
1.09%
0.32%
Debt
Debt current
169,400
18,200
53,500
Long-term debt
259,500
408,700
344,100
Deferred revenue
2,100
69,400
Other long-term liabilities
106,700
96,800
38,200
Net debt
(635,000)
(672,300)
(572,700)
Cash flow
Cash from operating activities
776,500
724,000
584,000
CAPEX
(362,000)
(284,600)
(253,400)
Cash from investing activities
(368,700)
(288,200)
(253,100)
Cash from financing activities
(459,600)
(293,600)
(168,100)
FCF
602,000
741,500
728,900
Balance
Cash
853,900
894,300
762,600
Long term investments
210,000
204,900
207,700
Excess cash
916,410
954,855
828,720
Stockholders' equity
3,398,400
2,823,600
2,315,900
Invested Capital
2,397,990
2,108,345
1,900,280
ROIC
41.65%
48.05%
59.26%
ROCE
31.88%
35.02%
41.08%
EV
Common stock shares outstanding
75,300
75,800
76,300
Price
352.12
49.62%
235.35
-49.82%
469.01
65.55%
Market cap
26,514,636
48.63%
17,839,530
-50.15%
35,785,463
66.64%
EV
25,879,636
17,167,230
35,212,763
EBITDA
1,198,100
1,198,300
1,245,300
EV/EBITDA
21.60
14.33
28.28
Interest
9,000
7,900
7,200
Interest/NOPBT
0.85%
0.73%
0.64%